Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)

Completed · Phase 1 · Has a placebo group

Conditions studied: HIV Infections, Depression

In brief

The primary purpose of this study was to test the whether high-risk, HIV-seronegative persons with mild-to-moderate depression would be more likely to adopt protective behavior change when provided with pharmacotherapy for their depression than when treated with placebo. High-risk behaviors include using illegal drugs and participating in unprotected sexual intercourse. The specific pharmacotherapy used in this study was the anti-depressant, bupropion. The subject population consisted of HIV negative men who have sex with men (MSM) with mild-to-moderate depression.

Key facts

Study ID

NCT00285584

Run by

NYU Langone Health

People needed

41

Starts

2002-09-01

Expected to finish

2004-09-01

Last updated by the study team

2017-12-12

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Available for at least 9 months, or the duration of the study
• Willing to complete HIV testing and counseling
• History of HIV testing and counseling
• At high risk of HIV infection, indicated by more than one male sexual partner in the 3 months prior to study entry
• Meets criteria for either (a) major depression or dysthymia within a mild-to-moderate level according to standard criteria DSM-IV, or (b) minor depression as defined by one or more of the following symptoms at any time and for any duration during the past 12 months: significant weight loss or gain, or significant decrease or increase in appetite; poor sleep pattern; noticeable irritability or slowness; fatigue or lack of energy; inappropriate feelings of worthlessness or guilt; inability to concentrate; indecisiveness; and recurrent thoughts of death or suicide.

You may not qualify if…

• HIV infected
• Sexual intercourse in the 3 months prior to study entry with only one partner, and in a monogamous relationship
• Currently enrolled in another study involving repeated HIV testing and counseling
• Receiving treatment for depression with antidepressant medication for any length of time within the year prior to study entry
• Currently in psychotherapy, psychoanalysis, or any other form of talk therapy for any reason
• Severe depression or at suicidal risk
• No evidence or prior history of depression
• Homicidal or other similar problem that, in the opinion of the investigator, may endanger study staff and participants
• Currently taking monoamine oxidase inhibitors (MAOIs). Participants may be allowed to enroll 14 days after discontinuing use of a MAOI.
• History of seizures
• History or current symptoms of bipolar disorder

Where it is running

• Bellevue Hospital Center — New York, New York, United States
• New York University School of Medicine — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.